Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
930.80
-16.30 (-1.72%) Zydus Lifesciences informs about press release
Date: 01-10-2022Zydus Lifesciences has informed that it enclosed a copy of press release dated October 1, 2022 titled ‘Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension’.
The above information is a part of company’s filings submitted to BSE.